ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "8aaa660f-118c-4bb4-a8c0-60d32162e162"}, "_deposit": {"id": "30080", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "30080"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00030080", "sets": ["2504"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "160", "bibliographicPageStart": "151", "bibliographicVolumeNumber": "82", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs. Clinical trials using anticancer drugs including antimetabolites or drugs targeted to cell cycle-related molecules failed to show superiority over conventional treatments. Recently, drugs targeted to Bcl-2, SMO, FLT3, and IDH1/2 have been shown to prolong overall survival alone or in combination with reduced-intensity chemotherapy. These treatments are likely to reshape the therapeutic landscape of AML, which will be personalized for individual patients based on leukemia genetics.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.82.2.151", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/822.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Naoe, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "99231", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-06-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "01_Naoe.pdf", "filesize": [{"value": "750.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 750600.0, "url": {"label": "01_Naoe.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/30080/files/01_Naoe.pdf"}, "version_id": "fd694a1b-ab66-453b-82e7-7b19b46ef039"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "elderly patients", "subitem_subject_scheme": "Other"}, {"subitem_subject": "acute myeloid leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "molecule-targeted drug", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prognosis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement"}]}, "item_type_id": "9", "owner": "1", "path": ["2504"], "permalink_uri": "https://doi.org/10.18999/nagjms.82.2.151", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-06-01"}, "publish_date": "2020-06-01", "publish_status": "0", "recid": "30080", "relation": {}, "relation_version_is_last": true, "title": ["How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 82(2)

How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement

https://doi.org/10.18999/nagjms.82.2.151
https://doi.org/10.18999/nagjms.82.2.151
a59a6af2-34c6-4067-825d-716fa8b7e1a6
名前 / ファイル ライセンス アクション
01_Naoe.pdf 01_Naoe.pdf (750.6 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2020-06-01
タイトル
タイトル How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement
著者 Naoe, Tomoki

× Naoe, Tomoki

WEKO 99231

Naoe, Tomoki

Search repository
キーワード
主題Scheme Other
主題 elderly patients
キーワード
主題Scheme Other
主題 acute myeloid leukemia
キーワード
主題Scheme Other
主題 chemotherapy
キーワード
主題Scheme Other
主題 molecule-targeted drug
キーワード
主題Scheme Other
主題 prognosis
抄録
内容記述 Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs. Clinical trials using anticancer drugs including antimetabolites or drugs targeted to cell cycle-related molecules failed to show superiority over conventional treatments. Recently, drugs targeted to Bcl-2, SMO, FLT3, and IDH1/2 have been shown to prolong overall survival alone or in combination with reduced-intensity chemotherapy. These treatments are likely to reshape the therapeutic landscape of AML, which will be personalized for individual patients based on leukemia genetics.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.82.2.151
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/822.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 82, 号 2, p. 151-160, 発行日 2020-05
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 09:07:51.680936
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3